You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

December 22, 2017

New Guidance Released on Class B, C, and D Medical Devices in Vietnam

Vietnam’s Ministry of Health (MOH) has recently issued a very important notification and new regulations relating to the implementation of Decree No. 36/2017/ND-CP (Decree 36) on medical device management. The key notification was issued under Official Dispatch No. 7165/BYT-TB-CT dated December 14, 2017 (Dispatch 7165). The new implementing guidelines for Decree 36 were issued under Circular No. 46/2017/TT-BYT dated December 15, 2017 (Circular 46). These developments are crucial to the registration regime for medical devices in Vietnam.

Dispatch 7165

While not relating to Class A medical devices (which include, for example bandages, wheelchairs, reusable surgical instruments, medical gloves, etc.), Dispatch 7165 provides specific guidance on Class B, C, and D devices, as well as in vitro diagnostic (IVD) biologicals. Class B medical devices include items such as blood centrifuges, diagnostic ultrasound scanners, and infusion cannulas, while Class C medical devices include items such as diagnostic X-ray equipment, electrosurgical units, and urethral stents. Class D medical devices include items such as absorbable sutures, arterioscopes, implantable infusion pumps, dental implants, etc.

A marketing authorization (MA) license for Class B, C, and D medical devices will only be required from January 1, 2019 onwards. This means that the MA regime for Class B, C, and D medical devices will be delayed for one year from the original date set forth under Decree 36. This delay is likely spurred on due to the imminent delays in registering massive amounts of medical devices that have never been registered before, especially when infrastructure and proper resources need to be bolstered among the registration teams/office of the MOH to handle the huge workload. The early deadlines to register all devices were not practicable and were over-ambitious goals.

From now until January 1, 2019, some specific interim regulations set forth under the new Official Dispatch are as follows:

  • Class B, C, and D medical devices which were included in the enclosed annex of Circular 30/2015/TT-BYT dated October 12, 2015 on promulgating the importation of medical devices (Circular 30) will continue to be governed by the regulations of Circular 30. This means the MOH is allowing these devices to be imported and circulated in Vietnam, provided that these devices have import licenses as stipulated in Circular 30, and have been properly classified as Class B, C, or D medical devices by the authorized organizations.
  • For Class B, C, and D medical devices which are not included in the enclosed annex of Circular 30, the MOH will allow these devices to be imported and circulated in Vietnam, provided that they have been properly classified as Class B, C, or D medical devices by the authorized organizations. For smooth customs clearance, in practice, these devices may also need a letter from the Department of Medical Equipment and Construction (DMEC) under the MOH to confirm that the imported medical devices are not included in the enclosed annex of Circular 30.
  • The importation and circulation of IVD biologicals (e.g., microbiology reagents, histology reagents, etc.) require an MA license (as stipulated in Circular 44/2014/TT-BYT on drug registration) or an import license (as stipulated in Circular No. 47/2010/TT-BYT). IVD biologicals with MA licenses can be imported until the expiry date of their MA licenses. For IVD biologicals with import licenses that expire on December 31, 2017, their import licenses can be extended if the expiry date on their Letter of Authorization (LOA) remains valid after December 31, 2017 and the importer submits a written extension request for the import license to the DMEC, which will then review the request and approve the extension at its discretion.  

Circular 46

Circular 46, which was just released, provides long-awaited implementing guidelines to Decree 36 and will enter into effect on February 1, 2018.

The Circular specifically states that Class C and D medical devices that are put into the human body are exempt from the requirement to submit summaries of clinical testing data and clinical testing research results. These medical devices include (1) medical devices in Annex I of the Circular (e.g., peritoneal dialysis catheters, cannulae, introducers, etc.), and (2) medical devices which are freely sold and have obtained certificates of free sale from a competent body of any of the countries and organizations which are set forth in Annex II of the Circular.

Class C or D IVD medical devices (e.g., HIV blood donor screening equipment, HIV blood diagnostic equipment, plasma bags, etc.) are also exempt from the requirement to submit test results if such medical devices have been freely sold and have obtained certificates of free sale from a competent body of any of the countries and organizations which are included in Annex II of the Circular. Annex II countries include Japan, Canada, the United States, and various European countries.

The Circular also includes a list (i.e., Annex III) of Class B, C, and D medical devices which may be traded like other normal goods, and imposes no requirements on the establishments trading them to declare their eligibility to trade in medical devices.

Additionally, the MOH issued guidance on presenting technical summaries, and requirements and terminology for Vietnamese to English translations for the LOA. A sample LOA is also promulgated under the Circular.

Technical summaries and English LOAs which were signed before the effective date of the Circular (February 1, 2018) will continue to be used; companies are not required to re-prepare these documents.

RELATED INSIGHTS​ 

July 8, 2025
On July 3, 2025, Vietnam’s Ministry of Health (MOH) issued Circular No. 34/2025/TT-BYT amending some articles of Circular No. 06/2011/TT-BYT on the management of cosmetics products (Circular 34), which provides the current regulations on the product notification process for cosmetics (cosmetic notification). Circular 34 will come into effect on August 18, 2025. Changes to Cosmetic Notification Some of the key stipulations of Circular 34 are outlined below. Addition of submission route for notification Circular 34 officially adds online submission via the National Public Service Portal as an accepted type of cosmetic notification, in addition to direct submission and submission via post. Clearer regulations on preparing cosmetic notification form Circular 34 provides clarification on the signing requirements for cosmetic notification forms. For online submissions, both e-signatures and digital signatures are accepted. For offline submissions, the circular explicitly states that stamped/generated signatures are not acceptable. There are no substantive changes to existing requirements regarding grouping of products in a single declaration, ingredient listing, or language used in the notification form. Circular 34 only introduces formatting adjustments to these provisions. Updated administrative procedures Circular 34 updates requirements on digital procedures and authentication for online submission with references to new government decrees. In addition, processing timelines for cosmetic notification are further clarified, in particular, five working days for feedback on incomplete dossiers and five working days for approval after receiving complete supplemental dossiers. Revised requirements for import of samples for testing and research An updated Appendix 14-MP form is introduced with Circular 34, in which the receiving authority is updated from the Drug Administration of Vietnam to the specialized health agency under the provincial People’s Committee. Both online and direct submission of the request are allowed. The approval timeline is three working days from the date of reviewing the request. Transition clause Notifications
July 8, 2025
On June 29, 2025, the government of Vietnam issued Decree No. 163/2025/ND-CP providing detailed guidance on the implementation of the amended Law on Pharmacy (Decree 163). Decree 163, like the amended Law on Pharmacy, took effect on July 1, 2025, officially replacing Decree No. 54/2017/ND-CP (Decree 54). The new decree introduces comprehensive regulations across key areas of pharmaceutical management such as pharmacy practice certificates, certificates of eligibility for pharmaceutical business, import and export of drugs and drug materials, GMP inspection of foreign manufacturers, drug and drug material recall, certificates of drug advertising content, and drug price management. Key Changes in Decree 163 Some outstanding changes and additions in Decree 163 are presented below. Destruction of Specially Controlled Drugs It is no longer required to obtain approval from the competent authority before the destruction of narcotic, psychotropic, and precursor drugs, and pharmaceutical ingredients that are narcotic or psychotropic substances, or precursors used in drugs. Instead, notification must be provided at least seven working days in advance, including the proposed destruction date and a detailed list of items to be destroyed. E-commerce in Pharmaceuticals Pharmaceutical businesses operating via e-commerce platforms must publicly disclose the following information to ensure transparency and consumer safety: (i) certificate of eligibility for pharmaceutical business, (ii) pharmacy practice certificate of the person responsible for pharmaceutical expertise, and (iii) drug information. Shelf-Life Requirements for Imported Products For drugs and ingredients with a total shelf life of nine months or less, at least one-third of the shelf life must remain at the time of customs clearance. Drugs with a shelf life of 30 days or less must still be within their shelf life at the time of clearance. Control of Imported Products Drugs subject to import control include all drugs with marketing authorization (MA), except for (i) drugs that
May 28, 2025
Tilleke & Gibbins attorneys in Vietnam have contributed the 2025 edition of Doing Business in Vietnam, a comprehensive Q&A-style resource from Thomson Reuters Practical Law that provides essential insights for companies navigating business operations in Vietnam. The guide presents a detailed overview of the country’s legal framework and regulatory environment, reflecting recent updates in Vietnamese legislation and practice. This annually updated guide offers key information on the following areas: Legal system: Structure of the Vietnamese judiciary and the role of codified law. Foreign investment: Conditions for market access, licensing requirements, foreign ownership restrictions, and investment incentives. Business vehicles: Formation and operation of legal entities, including limited liability companies, joint-stock companies, and representative offices. Employment: Employment contracts, social insurance, labor rights, and procedures for hiring foreign nationals. Tax: Overview of corporate income tax, personal income tax, value-added tax, and other tax obligations. Intellectual property: Procedures for protecting and enforcing patents, trademarks, copyrights, and other IP rights. Data protection: Compliance requirements under Vietnam’s data privacy laws, including the Personal Data Protection Decree. Competition law: Antitrust rules and regulatory oversight under the Law on Competition. Anti-bribery and corruption: Legal framework and enforcement practices aimed at curbing corrupt activities. E-commerce and digital business: Regulations governing online platforms, digital content, and cross-border services. Marketing and advertising: Laws and guidelines on advertising standards and consumer protection. Product regulation and liability: Safety requirements, product liability issues, and roles of relevant authorities. Doing Business in Vietnam is part of Practical Law’s global series of legal guides designed to support international practitioners and businesses. To access the most recent edition of the Vietnam guide, visit the Practical Law website and sign up for a free trial.
May 28, 2025
Thailand’s Food and Drug Administration (FDA) has launched a strategic collaboration with leading e-commerce platforms Lazada and Shopee to strengthen regulatory oversight of health-related products sold online. This partnership is part of a broader initiative to enhance consumer protection, enforce compliance with Thai health regulations, and foster a safer digital marketplace for health products. As part of this initiative, the Thai FDA is urging all sellers—particularly cross-border vendors—to secure proper FDA registration for their products before market entry. The objective is to ensure that only legally authorized, safe, and quality-assured healthcare products are available to Thai consumers. In pursuit of this goal, the FDA has been working closely with Lazada and Shopee to implement proactive surveillance mechanisms aimed at identifying and removing noncompliant, substandard, or unregistered products. This collaboration has already yielded measurable results. Between September 2023 and 2024, Lazada supported regulatory enforcement by removing 9,454 noncompliant listings and delisting 30 vendors. In addition, 134 sellers were subjected to legal proceedings for regulatory violations. Shopee has taken a similarly rigorous stance, committing to the immediate removal of products found to be in breach of FDA regulations. The platform has also provided educational materials for merchants and implemented consumer complaint mechanisms to enhance accountability. Looking ahead, the Thai FDA plans to roll out a data integration system utilizing API technology, enabling seamless and secure exchange of regulatory data between the agency and e-commerce platforms. This system will be supported by comprehensive training for both Thai FDA officials and e-commerce staff, with a particular focus on the use of the Thai government’s Law Enforcement Request Portal, a secure communication channel for coordinating enforcement actions between government agencies and platform operators. Additionally, a joint product inspection framework is currently under development in partnership with Lazada and Shopee. This framework will incorporate strict